Engineered target specific nucleases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11401512
APP PUB NO 20190241877A1
SERIAL NO

16271250

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SANGAMO THERAPEUTICS INC7000 MARINA BLVD BRISBANE CA 94005

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
DeKelver, Russell Richmond, US 20 721
Krivega, Ivan Richmond, US 3 4
Miller, Jeffrey C Richmond, US 104 3965
Zhang, Lei Richmond, US 2799 20393

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Feb 2, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 2, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 2, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00